Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

woraput/E+ via Getty Images Topline Summary Cellectar Biosciences (NASDAQ:CLRB) is a long-toothed developmental biotech focused on the development of a radiolabeled phospholipid for the management of hematologic malignancies, with Waldenstrom's macroglobulinemia being their main shot on goal. Very recently, they had a trial read out with what they believe are strong-enough data to justify and Accelerated Approval, and yet the company remains a microcap stock. While they have cash concerns and pipeline r ...